Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Verzenios ® (abemaciclib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Is Verzenios® (abemaciclib) dose adjustment required for patients with hepatic impairment?
Abemaciclib dose adjustments are only required for patients with severe hepatic impairment (Child-Pugh C). Decrease the dosing frequency to once daily in these patients.
Relative Potency and Half-Life of Abemaciclib increases in Patients with Severe Hepatic Impairment
No dose adjustments are necessary in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment.1
Abemaciclib is metabolised in the liver.
Mild (Child Pugh A) and moderate (Child Pugh B) hepatic impairment had no effect on the exposure of abemaciclib. In severe hepatic impairment (Child Pugh C), the potency adjusted unbound abemaciclib plus its active metabolites increased 2.4-fold. The half‑life of abemaciclib increased from 24 to 55 hours.1
1Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: 19 January 2022